712 related articles for article (PubMed ID: 21420906)
21. The role of serotonin in antipsychotic drug action.
Meltzer HY
Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):106S-115S. PubMed ID: 10432496
[TBL] [Abstract][Full Text] [Related]
22. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
Ichikawa J; Li Z; Dai J; Meltzer HY
Brain Res; 2002 Nov; 956(2):349-57. PubMed ID: 12445705
[TBL] [Abstract][Full Text] [Related]
23. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
Millan MJ
J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
[TBL] [Abstract][Full Text] [Related]
24. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
25. Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice.
Philibin SD; Prus AJ; Pehrson AL; Porter JH
Psychopharmacology (Berl); 2005 Jun; 180(1):49-56. PubMed ID: 15696329
[TBL] [Abstract][Full Text] [Related]
26. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
Meltzer HY; Massey BW; Horiguchi M
Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
van den Buuse M; Gogos A
J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
[TBL] [Abstract][Full Text] [Related]
29. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
30. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
[TBL] [Abstract][Full Text] [Related]
32. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism.
Chung YC; Li Z; Dai J; Meltzer HY; Ichikawa J
Brain Res; 2004 Oct; 1023(1):54-63. PubMed ID: 15364019
[TBL] [Abstract][Full Text] [Related]
33. Role of serotonin in the action of atypical antipsychotic drugs.
Meltzer HY
Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
[TBL] [Abstract][Full Text] [Related]
34. Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.
Adams W; van den Buuse M
Neuropharmacology; 2011 Sep; 61(3):458-67. PubMed ID: 21477601
[TBL] [Abstract][Full Text] [Related]
35. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
36. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
37. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release.
Ichikawa J; Chung YC; Dai J; Meltzer HY
Brain Res; 2005 Aug; 1052(1):56-62. PubMed ID: 16061211
[TBL] [Abstract][Full Text] [Related]
38. Targeting 5-HT receptors for the treatment of obesity.
Sargent BJ; Henderson AJ
Curr Opin Pharmacol; 2011 Feb; 11(1):52-8. PubMed ID: 21330209
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
Kuroki T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
[TBL] [Abstract][Full Text] [Related]
40. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
